The patient was treated with alectinib (600 mg twice per day) as first-line therapy as soon as the LTBP1-ALK and HIP1-ALK fusions were identified (March 31, 2020). After 1 month of therapy, the patient achieved complete remission of the clinical symptoms, including cough and shortness of breath, with no obvious adverse reaction other than mild constipation. CT scan images (April 27, 2020) revealed a significant response in the target lesion of the right lower lobe, which had obviously shrunk (4.0 cm × 3.0 cm), while the brain lesions had nearly disappeared. The patient achieved partial response (PR) according to the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) and until the last follow-up (November 03, 2021), the notable response was maintained (Figure 6). At the data cutoff (November 03, 2021), the patient remained on alectinib treatment, which had yielded a PFS of more than 19 months.